Study S001260

Semaglutide and Vascular Regeneration in People With Diabetes and/or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT05870462
Acronym: SEMA-VR
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: UNKNOWN
Enrollment: 100
Start: 2023-04-29
Primary completion: 2024-12
Lead sponsor: Canadian Medical and Surgical Knowledge Translation Research Group
Conditions: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Obesity
Interventions: DRUG:Semaglutide Pen Injector
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Changes in the mean frequency (%) of circulating ALDHhiSSClow primitive progenitor cells in individuals treated with semaglutide versus usual care for 6 months [Baseline to 6 months post-randomization]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012673	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Sattar N, The lancet. Diabetes & endocrinology	2021	Systematic review	PMID 34425083 DOI	registry reference RESULT:34425083
R0022440	Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Sorli C, The lancet. Diabetes & endocrinology	2017	Randomized trial	PMID 28110911 DOI	registry reference RESULT:28110911
R0022278	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP, The New England journal of medicine	2016	Randomized trial	PMID 27633186 DOI	registry reference RESULT:27633186
R0014170	The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ, Lancet (London, England)	2006	Narrative review	PMID 17098089 DOI	registry reference BACKGROUND:17098089